Novavax: US-Based Bio-technology Company
Current project: Development of a recombinant vaccine for COVID-19
A final efficacy of 96.4% against mild, moderate and severe disease caused by the original SARSCoV2 strain in a pivotal Phase3 trial in the U.K.
In January, the company reported that its vaccine had proved to have 89% efficacy in preventing infection in some trial volunteers in the U.K.
The Serum Institute of India has an agreement with Novavax to manufacture a substantial volume of the vaccine.